Cell Signaling Technology Logo - Extra Large
1% for the planet logo
Trial Size Available Flag
Recombinant Flag
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

IGSF8 (F6M8L) Rabbit mAb #91585

Filter:
  • WB

    Product Specifications

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa) 70
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    IGSF8 (F6M8L) Rabbit mAb recognizes endogenous levels of total IGSF8 protein.

    Species Reactivity:

    Human

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Val30 of human IGSF8 protein.

    Background

    Immunoglobulin superfamily member 8 (IGSF8), also known as CD316 or EWI-2, is a type-I transmembrane protein that belongs to the immunoglobulin superfamily (1-3). IGSF8 was initially characterized as a binding partner with CD9 and CD81, regulating vesicle trafficking (1). Recent work has focused on the role of IGSF8 in various cellular functions, such as cell motility, cell adhesion, innate immunity, neural development, and tumor biology (1-4). IGSF8 can act as a checkpoint for innate immunity by inhibiting natural killer (NK) cell response in cancer immunotherapy (3,7). Curiously, IGSF8 can exhibit contrasting roles in tumors, acting either as a tumor suppressor or an oncoprotein. In certain solid tumor cancers, such as lung, skin, prostate, and brain, IGSF8 suppresses tumor progression by inhibiting proliferation and metastasis (2,6-7). In contrast, in hematological malignancies like leukemias, IGSF8 sustains cancer cell stemness, which promotes therapy resistance and disease progression (6,8,9). IGSF8 has recently emerged as an innate immune checkpoint molecule in the tumor microenvironment (TME) (6). By inhibiting NK cell-mediated interactions with immune inhibitory receptors, IGSF8 reduces cytotoxicity, contributing to immune evasion in immunologically “cold” tumors, making the protein an interesting therapeutic target (6-8). test
    For Research Use Only. Not for Use in Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.